Antibiotic Treatment Guidelines

Introduction to Antibiotic Treatment

Antibiotic treatment duration and approach should be tailored to the site and severity of infection, with specific durations recommended for different types of infections, as recommended by the American Thoracic Society, with a strength of evidence of moderate 1, 2
The European Urology Association and the Infectious Diseases Society of America recommend maintaining treatment for 7-10 days, which can be extended up to 14 days due to patient comorbidities such as diabetes and chronic kidney disease 3

Antimicrobial therapy is crucial for treating various infections, and guidelines recommend considering local resistance patterns and patient-specific factors when selecting antibiotics, as recommended by the Infectious Diseases Society of America, with a strength of evidence of high 3, 1, 4, 5, 6
The European Urology guidelines recommend levofloxacin for its once-daily dosing and better coverage against respiratory pathogens, while ciprofloxacin is preferred for its superior activity against Pseudomonas aeruginosa 3, 6

The following dosing regimens are recommended:

Antibiotic	Dose
Ciprofloxacin	400mg IV twice daily for most infections [3, 7, 8]
Levofloxacin	500mg oral once daily as the standard, with high-dose/short-course options available, and 750mg IV once daily [3, 7]
Piperacillin-tazobactam	3.375g IV q6h or 4.5g IV q6h [7]
Ticarcillin-clavulanic acid	3.1g IV q6h [7]
Ceftazidime	2g IV q8h [7, 8]
Cefepime	2g IV q8-12h [7, 8]
Meropenem	1g IV q8h [7, 8]
Imipenem/cilastatin	500mg IV q6h or 1g IV q8h [7]
Doripenem	500mg IV q8h [7]
Amikacin	15-20mg/kg IV q24h [7]
Gentamicin	5-7mg/kg IV q24h [7]
Tobramycin	5-7mg/kg IV q24h [7]

For patients who are penicillin-allergic, Aztreonam may be administered at a dose of 1-2g IV q6-8h, as recommended by the Centers for Disease Control and Prevention 9, 7, 8
Preferred oral options for Pseudomonas aeruginosa are ciprofloxacin 500mg BID or levofloxacin 750mg daily 10

Patients with diabetes are more vulnerable to complications of pyelonephritis, including renal abscesses, and require more frequent monitoring of renal function, as suggested by the Journal of the American College of Radiology 11
Patients with complicated pyelonephritis due to Pseudomonas aeruginosa should receive treatment for 7-10 days, and those with comorbidities like diabetes may require extended treatment of up to 3-4 weeks, as indicated by the American College of Radiology 12
The Infectious Diseases Society of America recommends against stopping antibiotics upon reaching clinical stability in patients with Pseudomonas aeruginosa infections, requiring complete treatment for eradication, with a strength of evidence supported by Clinical Infectious Diseases and Diabetes/Metabolism Research and Reviews 13, 14
The total duration of antibiotic therapy should be 3-4 weeks for septic arthritis, with a strength of evidence of high 15

Therapeutic drug monitoring for aminoglycosides (peak and trough levels) and following inflammatory markers (ESR, CRP) to assess treatment response are important considerations, as suggested by the Clinical Microbiology and Infection society, with a strength of evidence of high 1, 15
Culture and susceptibility testing should be performed periodically during therapy to monitor for resistance development, as recommended by the Clinical Microbiology and Infection society, with a strength of evidence of high 1
The American Heart Association recommends being vigilant for signs of mycotic aneurysm development (fever, increasing aneurysm size, persistent bacteremia) which would require more aggressive intervention 16
The Clinical Microbiology and Infection society recommends considering P. aeruginosa in patients with ≥2 of the following risk factors: recent hospitalization, frequent/recent antibiotics, severe underlying disease, or oral steroid use 17
The European Association of Urology recommends always evaluating for urological abnormalities or foreign bodies that may complicate treatment 3

Outpatient parenteral antibiotic therapy (OPAT) is a safe and effective alternative for clinically stable patients who require parenteral antibiotics, allowing for normal activity and being a viable and cost-effective alternative to hospitalization, as suggested by the European Respiratory Society 18
Patients require stable venous access, adherence to treatment, regular clinical and laboratory follow-up, and support from a multiprofessional team for successful OPAT, as recommended by the European Respiratory Society and supported by research in Diabetes/Metabolism Research and Reviews 18, 12
The first dose of antibiotics should be administered under medical supervision to monitor for adverse reactions, and patients should receive written instructions on how to administer antibiotics and recognize warning signs, with 24-hour telephone contact available for emergencies, as suggested by the European Respiratory Society 18